Conference Presentation, Interview
Revolutionizing Cancer Treatment with Immunotherapy: Talks at GS Session Highlights
Goldman SachsGiovanni Caforio, Laurie Glimcher, Jill O'Donnell-Tormey, Dr. Giovanni Coforio, Dr. Lori Glimcher, Jamie
- Immunotherapy Mechanism: Treatments harness the patient's innate immune system rather than directly attacking cancer cells via radiation or traditional chemotherapy.
- Normal cells display surface markers ignored by the immune system, whereas mutated cancer cells develop distinct markers that should signal an attack.
- Cancer cells often co-opt natural immune mechanisms to inhibit T cells, effectively "shutting off" the immune response to allow tumor spread.
- Checkpoint blockers function by inhibiting these regulatory signals, thereby reactivating T cells to identify and destroy tumor cells.
- Evolution of Cancer Treatment: Cancer therapy has progressed through sequential modalities: surgery, chemotherapy, radiation, targeted therapies, and finally immuno-oncology.
- While surgery and chemotherapy may cure early-detected, non-metastasized tumors, metastatic cancer remains difficult to treat with these methods alone.
- Chemotherapy is characterized as a non-specific "hammer" approach that destroys cancer cells but also damages normal tissue, leading to significant toxicity.
- Immuno-oncology is described as a more personalized, guided approach that is significantly less toxic by activating the body's own surveillance mechanisms.
- Clinical Efficacy and Trends: Early trials conducted in melanoma demonstrated remarkable success rates within five to six years.
- Over 60% of melanoma patients now respond to checkpoint inhibitor treatments.
- Approximately 17% of melanoma patients achieve a total response, showing no signs of active disease.
- Survival rates for melanoma patients exceed 60-70% after one year of treatment.
- Lung cancer has seen rapid adoption of immuno-oncology, with 80-90% of patients receiving these agents.
- In lung cancer, the use of chemotherapy has virtually disappeared in the first-line setting as response rates and survival have doubled compared to historical standards.
- Melanoma treatment has largely eliminated chemotherapy in favor of combination immunotherapies.
- Future Outlook and Challenges: The field aims to "raise the tail of the curve," increasing the percentage of patients who respond to treatment.
- Complete elimination of chemotherapy is not envisioned; it is expected to remain relevant for specific tumor types and early lines of therapy.
- Treatment strategies are shifting toward personalization based on the unique genetic mutations of each patient's tumor.
- Non-responsiveness in some patients is attributed to the multi-step complexity of the immune response and the dynamic, "wily" nature of tumors.
- Success requires T cell activation, circulation to the tumor site, and overcoming the tumor's ability to suppress the immune system.
- Experts characterize the current era as a beginning of a long but promising journey requiring collaboration across the medical community.